We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Unilever Plc | LSE:ULVR | London | Ordinary Share | GB00B10RZP78 | ORD 3 1/9P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
51.00 | 1.25% | 4,133.00 | 4,137.00 | 4,139.00 | 4,146.00 | 4,097.00 | 4,100.00 | 4,574,072 | 16:35:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Perfume,cosmetic,toilet Prep | 59.6B | 6.49B | 2.5958 | 15.94 | 103.38B |
Date | Subject | Author | Discuss |
---|---|---|---|
17/1/2022 10:44 | Jope has just signed his own death warrant, shareholders will never approve this and his tenure now looks toast. Bought a very small amount. Pushed down further at the US open?. | essentialinvestor | |
17/1/2022 10:38 | there has been talk of pe interest in unilever. maybe the ceo has rushed into doing something to avoid a takeover attempt. it seems that when it comes to his own job he is quite proactive. other than a takeover or change at the top, its hard to see the shares moving markedly higher. | roguetraderuk | |
17/1/2022 10:27 | BARCLAYS CUTS UNILEVER PRICE TARGET TO 4,600 (4,800) PENCE - 'OVERWEIGHT' | philanderer | |
17/1/2022 10:26 | This would have been a blue day if not for the buying of GSK unit | nick100 | |
17/1/2022 10:23 | RKT responding well this morning. | philanderer | |
17/1/2022 10:22 | Market will not allow the deal is what the share price is indicating. Beginning of the end for the CEO at a guess. | essentialinvestor | |
17/1/2022 10:17 | They should respond immediately by withdrawing. | pander45 | |
17/1/2022 10:16 | How long will it take unilever board to see that the market does not like this deal by over paying. | nick100 | |
17/1/2022 10:15 | How to destroy your company, chapter 1. Eyes greedier than belly. | pander45 | |
17/1/2022 10:09 | Market usually loves this sort of deal making, so for the ULVR share price to react so negatively tells you all you need to know that this is a hare-brained deal. To ram this through, serious debt would need to be taken on, the dividend would probably need to be cut for awhile, there'd also likely be some disposals (lots of value lost to the investment banks and government). A lot of pain would have to be taken to buy an asset that isn't cheap to acquire, will be low growth and has questionable synergy value. I think in the longer-term, there's a very real prospect that Unilever itself may become a target. It's performing so poorly under the current weak management, is valued well below peers in the US and has already seen a bid from Kraft/Buffett rebuffed. Given how badly the company has performed the last bid I think Unilever is in a much weaker position to knock back any new bids. Needless to say, as a shareholder I am really annoyed by this management team. Terry Smith really nailed it in his comments last week. It's time for shareholders to vote them out during the next AGM. | tabhair | |
17/1/2022 10:00 | Falling knife. Drip feed purchases if you're keen to buy. Personally, I'm watching from the sidelines and can't see any rush to get involved. | 25guilderbag | |
17/1/2022 09:48 | Terry Smith timing on his article superb, I would imagine a lot of happy investors sold at higher level, saving around 6% of their investment capital. | montyhedge | |
17/1/2022 09:46 | Terry Smith was right, these guys have totally lost their marbles. They've got enough brands and enough global coverage, if they focus on organic growth and margin expansion they will deliver for shareholders. I guess there's no fun in that. | squeamish1 | |
17/1/2022 09:45 | chart looks ugly. take a look at the 10 year chart and look at the rolling top since 2017. if the chart was the other way up, longs would be rubbing their hands in glee. but its not and just on pure techs, the target would be low 20's. thats a lot of value destruction that needs to happen but i think that might be avoided with a bid before it got that low. at present someone needs to offer 50 quid for the board to accept, but down there 46 quid might be accepted if the shares are in the low 30's. to put things into context on how badly the mkt views this action by unilever is that the shares are almost at the covid lows, a point where the world seemed to be ending. | roguetraderuk | |
17/1/2022 09:37 | I think you mean reversion steve3etc but revulsion will do nicely. | keyno | |
17/1/2022 09:31 | This is proving to be an expensive day :( | marksp2011 | |
17/1/2022 09:27 | The combined value of gsk/Ulvr fallen on that news. Can’t imagine this deal will go through | big7ime | |
17/1/2022 09:20 | Another one here who thinks it's mad to gear up £50/60Bn. FWIW I have bought a maiden Unilever holding to supplement a larger holding held in various ITs. £36.77 seems to take out Covid low and 3 year low so revulsion probably hereabouts? To think Unilever turned away £50 a few years ago. Get that Jope on the phone. | steve3sandal | |
17/1/2022 09:17 | My GSK Holding is over 2x ULVR so not unduly concerned about news. Main concern for ULVR is to not get into a bidding war and overpay particulary if their paper gets any weaker. $50 billion is about right. I guess GSK holding out for cash in full. A lot of debt for ULVR to take on at these uncertain times so cash call would be on the cards. | rogerrail | |
17/1/2022 09:14 | GlaxoSmithKline shares were up 5.2% early Monday, while Unilever shares were down 5.8%. Analysts at Bernstein cut Unilever shares to Underperform from Market-Perform (Alliance News) | philanderer | |
17/1/2022 09:09 | I see a private equity offer soon. All imho. | pander45 | |
17/1/2022 09:06 | If I were gsk I wouldn't be accepting any ULVR paper with this idiot in charge | spoole5 | |
17/1/2022 08:58 | This is becoming a target now. | pander45 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions